Abstract
FTI Consulting will report first-quarter 2026 financial results on April 30, 2026 Pre-Market; current projections center on revenue of about 971.03 million US dollars and adjusted EPS near 2.07, with investor attention on execution across Corporate Finance & Restructuring, Technology-enabled analytics in healthcare, and delivery efficiency under a new finance leadership team.Market Forecast
For the quarter ended March 31, 2026, market estimates indicate revenue of 971.03 million US dollars, up 7.11% year over year, adjusted EPS of 2.07, up 15.24% year over year, and EBIT of 88.55 million US dollars, up 32.89% year over year. Forecasts do not include explicit gross margin or net profit margin targets for the period.Within the company’s principal lines of work, management activity and recent senior hires suggest steadier delivery in core advisory and disputes practices with selective expansion in analytics-led offerings, supporting a measured growth outlook. The most promising commercial thrust highlighted by recent personnel moves is Technology-enabled data analytics in healthcare, with the Technology segment’s revenue base at 373.88 million US dollars and growth contributions expected to build on top of the company’s 10.71% year-over-year total revenue increase in the fourth quarter of 2025.
Last Quarter Review
In the fourth quarter of 2025, FTI Consulting delivered revenue of 990.75 million US dollars, a gross profit margin of 31.05%, GAAP net profit attributable to shareholders of 54.53 million US dollars with a net profit margin of 5.50%, and adjusted EPS of 1.78, up 14.10% year over year. A notable highlight was the outperformance versus market expectations, as revenue exceeded estimates by 72.19 million US dollars and adjusted EPS topped projections by 0.32, alongside EBIT growth of 53.24% year over year.Across the main businesses, Corporate Finance & Restructuring remained the largest contributor by revenue base at 1.55 billion US dollars for the period measured, while Forensic and Litigation Consulting and Economic Consulting added 764.69 million and 720.83 million US dollars respectively; segment-level year-over-year growth rates were not disclosed in the collected data, but the overall top-line advanced 10.71% year over year.
Current Quarter Outlook
Core Advisory Engine: Corporate Finance & Restructuring
Corporate Finance & Restructuring is positioned to be a key determinant of near-term performance given its scale and sensitivity to corporate activity and court-supervised processes. The latest quarter’s estimates for the company imply higher earnings leverage relative to top-line growth, which typically requires disciplined utilization, steady bill rates and project mix skewed toward higher-intensity engagements. Internally, the business benefits from the company’s global access to complex restructuring mandates and operational transformation work, as evidenced by mandates and special situations requiring court oversight and independent advisory capabilities. The expected year-over-year growth profile for the March quarter (revenue up 7.11%, EBIT up 32.89%) implicitly assumes favorable mix and efficient delivery, conditions that usually emerge when large mandates are active and senior teams stay well utilized.Pipeline visibility should be aided by multi-jurisdictional projects and cross-practice collaboration, which often enrichs fees and duration. Execution risk rests in timing: large restructuring and transformation engagements can ramp or pause around client milestones, and phasing can move revenue between quarters. Given that adjusted EPS is forecast to grow faster than revenue, effective cost management and travel and support expense discipline are likely to be essential to sustain margin momentum, particularly if pass-through or reimbursable items dilute gross margin optics.
Scaling Digital and Analytics: Technology and Healthcare Data
Technology-enabled services are a focal point for growth this year, reinforced by senior hires and partnerships announced recently. On April 22, 2026, the company expanded its Health and Human Services practice by adding experienced senior professionals in data analytics and AI, complementing earlier initiatives to enhance healthcare revenue-cycle and analytics capabilities. This follows the December 17, 2025 collaboration with a healthcare-focused automation platform aimed at improving revenue cycle management for provider clients; together, these actions signal investment to deepen domain expertise and broaden the analytics-led offering set. Over time, these capabilities can drive higher-value engagements across matters that require data engineering, predictive modeling, and advanced workflows, supporting rate resilience and cross-sell opportunities into Forensic and Litigation Consulting and Economic Consulting matters.Technology’s revenue base of 373.88 million US dollars provides a platform to scale these initiatives. Near-term contribution will depend on conversion of new capabilities into contracts and the pace at which clients adopt AI-enabled workflows in sensitive, regulated environments like healthcare. The quarter’s EPS estimate outpacing revenue growth suggests early-stage operating leverage if teams are kept highly utilized and delivery is standardized across engagements. Watch for indications of pipeline conversion in healthcare analytics, win rates on large matters, and the extent to which cross-practice teams bundle analytic modules into broader advisory mandates during the quarter.
Key Stock Price Drivers This Quarter
The most immediate stock driver will be the earnings bridge between revenue growth of 7.11% year over year and the faster pace of EBIT and EPS expansion, which implies favorable mix, utilization, and compensation balance across practices. Utilization and average bill rates are the two operational levers that can validate the EBIT estimate of 88.55 million US dollars; if the mix shifts toward higher-complexity mandates in Corporate Finance & Restructuring and contentious matters supported by Economic Consulting and Forensic and Litigation Consulting, margins can expand even without dramatic revenue acceleration. Conversely, a larger share of pass-through costs or a temporary lull in large matters could compress reported margins despite healthy backlog.Capital returns and balance sheet signaling also matter. The company disclosed substantial share repurchases completed during 2025, totaling 858.70 million US dollars in the fourth quarter, which reduced share count and supported per-share metrics into year-end. Continuation or moderation of this pace can influence adjusted EPS mechanics in 2026, especially as earnings growth composes with lower average shares. Governance and financial stewardship are also in focus following the March 9, 2026 appointment of a new Chief Financial Officer; commentary around capital allocation, headcount planning, and technology investment cadence can sway sentiment if aligned with the implied EBIT-to-EPS leverage in current estimates.
Investors will also be attentive to booking trends and staff deployment across geographies and practices. Multiple senior hires announced in the first months of 2026—in healthcare analytics and in operational improvement for resources sectors—suggest the firm is adding capacity in targeted verticals with data-heavy, performance improvement mandates. For the March quarter, qualitative updates on client demand in healthcare analytics, ongoing court-mandated sale processes and restructurings, and the cadence of disputes and investigations can help reconcile whether revenue tracks the 971.03 million US dollars estimate and whether margin mix supports the 2.07 adjusted EPS estimate. The degree of alignment across these factors is likely to drive the immediate post-release reaction.
Analyst Opinions
Bullish views currently dominate the limited ratings and commentary captured in the period from January 1, 2026 through April 23, 2026. William Blair, through analyst Andrew Nicholas, maintained a Buy rating on the shares in late-year and reaffirmed a constructive stance on the company’s prospects. With no identifiable bearish ratings or downgrades in the collected window, the observed ratio of bullish to bearish opinions stands at 100% to 0%, aligning with consensus expectations that anticipate revenue of 971.03 million US dollars and adjusted EPS of 2.07 for the quarter ended March 31, 2026.The bullish case emphasizes durable demand across the company’s advisory and disputes suites, supported by observable execution and outperformance in the fourth quarter of 2025—revenue beat of 72.19 million US dollars and adjusted EPS beat of 0.32—providing momentum into the new year. Analysts positive on the name point to several reinforcing elements: the acceleration implied by EBIT estimates rising 32.89% year over year in the March quarter, targeted expansion in Technology-enabled analytics for healthcare that can lift realization rates over time, and continued capital returns that support per-share earnings growth. They also view the new finance leadership as an opportunity to sharpen reporting discipline and capital allocation, potentially enhancing investor confidence if guidance ranges and conversion metrics remain consistent.
Another anchor of the constructive view is the company’s ability to staff and integrate senior practitioners in areas with complex, data-centric mandates. The April 22, 2026 additions in healthcare data analytics & AI and recent senior appointments in performance improvement for resources sectors illustrate a repeatable playbook: bring in domain experts who can extend the depth of advisory and technology offerings, then cross-sell into adjacent practices. Bullish analysts consider this approach conducive to sustained bill rate strength and higher utilization, which can translate into incremental EBIT margin when utilization is kept near targeted ranges. This operating framework helps explain how the consensus sees adjusted EPS growing faster than revenue in the quarter.
Finally, advocates highlight balancing factors that can mitigate near-term variability. Even if a single large matter’s timing pushes revenue between quarters, the diversified engine across Corporate Finance & Restructuring, Economic Consulting, Forensic and Litigation Consulting, Technology, and Strategic Communications allows the company to deploy staff where demand is most urgent and margin-rich. Coupled with ongoing share repurchases—858.70 million US dollars in the fourth quarter of 2025—per-share metrics can be supported through capital returns while earnings compound. In sum, the majority view expects the March quarter to validate the path to higher-quality earnings via mix and utilization, with revenue near 971.03 million US dollars and adjusted EPS around 2.07, leaving investors focused on whether commentary around pipelines and hiring confirms the trajectory into the rest of 2026.